FDA Regulation of Dietary Supplements and Requirements Regarding Adverse Event Reporting

被引:36
|
作者
Frankos, V. H. [1 ]
Street, D. A. [2 ]
O'Neill, R. K. [3 ]
机构
[1] US FDA, Div Dietary Supplement Programs, College Pk, MD USA
[2] US FDA, Emergency Response & Surveillance Branch, College Pk, MD USA
[3] US FDA, Div Publ Hlth & Biostat, College Pk, MD USA
关键词
D O I
10.1038/clpt.2009.263
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In 1994, the Dietary Supplement Health and Education Act (DSHEA) amended the Federal Food, Drug, and Cosmetic Act (FDC Act) to set up a distinct regulatory framework for what we now call dietary supplements. The DSHEA was passed with the intent of striking a balance between providing consumers access to safe dietary supplements to help maintain or improve their health and giving the US Food and Drug Administration (FDA) authority to regulate and take action against manufacturers of supplements or supplement ingredients that present safety problems, are presented with false or misleading claims, or are adulterated or misbranded. This article will present FDA's recent experience in collecting and evaluating dietary supplement adverse event data for the purpose of assuring the public that the dietary supplements they purchase are safe.
引用
下载
收藏
页码:239 / 244
页数:6
相关论文
共 50 条
  • [31] Data Mining of the Public Version of the FDA Adverse Event Reporting System
    Sakaeda, Toshiyuki
    Tamon, Akiko
    Kadoyama, Kaori
    Okuno, Yasushi
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2013, 10 (07): : 796 - 803
  • [32] An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System
    Geetha Iyer
    Sathiya Priya Marimuthu
    Jodi B. Segal
    Sonal Singh
    Drug Safety, 2017, 40 : 799 - 808
  • [33] Association between GvHD and nivolumab in the FDA adverse event reporting system
    Oshima, Y.
    Tanimoto, T.
    Yuji, K.
    Tojo, A.
    BONE MARROW TRANSPLANTATION, 2017, 52 (10) : 1463 - 1464
  • [34] Association between GvHD and nivolumab in the FDA adverse event reporting system
    Y Oshima
    T Tanimoto
    K Yuji
    A Tojo
    Bone Marrow Transplantation, 2017, 52 : 1463 - 1464
  • [35] Indoor tanning injuries: an evaluation of FDA adverse event reporting data
    Dowdy, John C.
    Sayre, Robert M.
    Shepherd, James G.
    PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 2009, 25 (04) : 216 - 220
  • [36] A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab
    Chen, Zepeng
    Li, Ming
    Li, Shuzhen
    Li, Yuxi
    Wu, Junyan
    Qiu, Kaifeng
    Yu, Xiaoxia
    Huang, Lin
    Chen, Guanghui
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (04) : 339 - 342
  • [37] The FDA Drug Safety Surveillance Program: Adverse Event Reporting Trends
    Weiss-Smith, Sheila
    Deshpande, Gaurav
    Chung, Stephanie
    Gogolak, Victor
    ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (06) : 591 - 593
  • [39] A disproportionality analysis of FDA adverse event reporting system events for misoprostol
    Li Yang
    Wenting Xu
    Scientific Reports, 15 (1)
  • [40] A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)
    Zou, Wenbin
    Yang, Han
    Xi, Yu
    Zeng, Chenxi
    Chen, Wei
    Fu, Xiangning
    HELIYON, 2024, 10 (17)